Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$30,000.00
Jun 1, 2026
For-profit organization
Youth - Biomedical Engineer
1042699
The graduate will support the Firm in developing a clinically deployable movement analysis platform using smartphone-based capture and cloud-based processing to generate 3D gait kinematics.
$49,995.00
Jun 1, 2026
Not-for-profit organization or charity
Germany and Poland Technical Tour.
1042743
Educational tour about the prefabrication ecosystem of wooden construction (panels, modules, structural component systems, high performance) in German and Poland.
$75,000.00
Jun 1, 2026
For-profit organization
Autonomous Alignment of Robots with Docking Station
1043767
Develop a computer vision based alignment system for autonomous mobile robots. The system will enable the mobile robots to interact with different attachments without human supervision.
$50,000.00
Jun 1, 2026
For-profit organization
ICAP 2026 –Scotland– International Co-Innovation Action Plan - Autonomous Containerized QSR MRF
1043802
This International Co-Innovation Action Program (ICAP) project will prepare the firm to enter into future international co-innovation work in Scotland.
$13,530.00
Jun 1, 2026
For-profit organization
Scaling-up Production of Coffee Cream Product
1043829
Project to scale-up ready-to-mix coffee-cream product for coffee based cocktails and unconventional hot and cold coffee drinks.
$75,000.00
Jun 1, 2026
For-profit organization
embedding AI agents
1043835
AI agents product improvments
$30,000.00
Jun 1, 2026
For-profit organization
Youth Program - AI Data Analyst
1043865
To provide employment for a recent software engineering graduate, the candidate will develop the firm’s AI-driven safety analytics and compliance platform.
$30,000.00
Jun 1, 2026
For-profit organization
Embedded Electronics
1043874
Development of a next-generation satellite communication device that implements the 3GPP Non-terrestrial Network (NTN) protocol.
$30,000.00
Jun 1, 2026
For-profit organization
Creative Digital Storytelling Internship
1043895
Moonlite Media Inc. (Moonlite Labs) will hire a full-time youth Creative Marketing & Digital Media Storyteller to support marketing, multimedia content production, community engagement, and brand storytelling for its Canadian AI-powered content creation platform.
$144,000.00
Jun 1, 2026
For-profit organization
Advancing a Selective EGFR-TKI Inhibitor to Overcome Drug Resistance in Lung Cancer
1043904
Rane Pharmaceutical is developing novel small molecule therapy to treat drug resistant Non-Small Cell Lung Cancer (NSCLC). Over 30,000 Canadians are diagnosed annually with this type of lung cancer. Conventional treatments face drug resistance which remains a major barrier with no current secondary options. Having validated novel compounds, Firm intends to develop a therapeutic that addresses a massive unmet need of cancer drug resistance.